Amman:Representing His Majesty King Abdullah II, His Royal Highness Prince Talal bin Muhammad honoured the winners of the 2026 King Hussein Cancer Research Award. The ceremony was attended by Her Royal Highness Princess Ghida Talal, Chairperson of the Board of Trustees of the King Hussein Cancer Foundation and Center, along with several members of the Royal Family.
According to Federation of Arab News Agencies, Princess Ghida praised the Arab researchers for their contributions to cancer research, highlighting their efforts in advancing scientific discoveries and improving patient care. The award is designed to recognize outstanding contributions to cancer research, encourage the development of better prevention and treatment methods, and promote scientific collaboration on both regional and international levels.
This year's ceremony celebrated researchers chosen from hundreds of applicants spanning more than 26 countries. Nizar Tannir from the University of Texas MD Anderson Cancer Center was awarded the Special Excellence in Scientific Research Award, and Amer Zeidan from Yale Comprehensive Cancer Center received the International Lifetime Achievement Award. Imam Waked of Menoufia University was recognized with the Regional Lifetime Achievement Award.
The Emerging Researcher Awards were bestowed upon Maryam Shalaby from the Netherlands Cancer Institute in the International Track and Omnia Atallah from the Arab Academy for Science, Technology and Maritime Transport in the Regional Track. The Promising Researcher Grants were given to Zaid Abdul Rahman of the King Hussein Cancer Center and Philip Hussein Qobeissi from the Lebanese American University.
Additionally, the center’s Bone Marrow Transplant, Cellular Therapy, and CAR-T Cell Therapy Programme was awarded the Professional Development Programme Award for Excellence in Cancer Patient Care. The award, launched in 2020 in memory of the late King Hussein bin Talal, aims to strengthen Arab cancer research and support scientific efforts to enhance cancer prevention and treatment. Since its inception, it has received more than 950 applications from over 30 countries, reviewed by international experts.